Erythropoietin: An update on the therapeutic use in newborn infants and children

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 5, 2005, Pages 723-734

  Donato, Hugo ^a,b  

^a Sanatorio de la Trinidad   (Argentina)

^b NONE   (Argentina)

Author keywords

Anaemia of prematurity; Cancer; Epoetin; Erythropoietin; Haemolytic anaemias; Haemolytic uremic syndrome; HCV infection; Hereditary spherocytosis; HIV infection; Nephrotic syndrome; Neuroprotection; Pure red cell aplasia; Renal failure; Rh haemolytic disease; Thrombocytosis

Indexed keywords

ALPHA INTERFERON; ALPHA TOCOPHEROL; ERYTHROPOIETIN RECEPTOR; FOLIC ACID; HEMOGLOBIN; IRON; PLACEBO; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; ZIDOVUDINE;

ANEMIA; ANEMIA OF PREMATURITY; ANTIBODY PRODUCTION; BLOOD TRANSFUSION; BRAIN HYPOXIA; CANCER; CEREBROVASCULAR ACCIDENT; CHILD CARE; CHILDHOOD DISEASE; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG USE; DRUG WITHDRAWAL; ERYTHROCYTE APLASIA; FLU LIKE SYNDROME; HEMATOLOGIC DISEASE; HEMOGLOBIN DETERMINATION; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; HYPERTENSION ENCEPHALOPATHY; HYPOREGENERATIVE ANEMIA; INTESTINE MUCOSA; INTRAUTERINE BLOOD TRANSFUSION; IRON BLOOD LEVEL; KIDNEY DISEASE; KIDNEY FAILURE; NEUROPROTECTION; NONHUMAN; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PATIENT MONITORING; PROTEIN BLOOD LEVEL; REVIEW; SEIZURE; THROMBOCYTOSIS; THROMBOSIS;

ANEMIA; CHILD; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HUMANS; INFANT, NEWBORN;

EID: 19044370617     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.5.723     Document Type: Review

References (147)

1. FISHER JW: Erythropoietin: Physiology and pharmacology update. Exp. Biol. Med. (2003) 228:1-14.
2. KAELIN WG JR: The von Hippel-Lindau gene, kidney cancer, and oxygen sensing. J. Am. Soc. Nephrol. (2003) 14:2703-2711.
3. DERY MA, MICHAUD MD, RICHARD DE: Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. Int. J. Biochem. Cell Biol. (2005) 37:535-540.
4. LIM GB, DODIC M, EARNEST L et al.: Regulation of erythropoietin gene expression in fetal sheep by glucocorticoids. Endocrinology (1996) 137:1658-1663.
5. ZANJANI ED, PIXLEY JS, SLOTNICK N et al.: Erythropoietin does not cross the placenta into the fetus. Pathobiology (1993) 61:211-215.
6. CAMPBELL J, WATHEN N, LEWIS M et al.: Erythropoietin levels in amniotic fluid and extraembryonic coelomic fluid in the first trimester of pregnancy: Br. J. Obstet. Gynaecol. (1992) 99:974-876.
7. ZANJANI ED, ASCENSAO JL, MCGLAVE PB et al.: Studies on the liver to kidney switch of erythropoietin production. J. Clin. Invest. (1981) 67:1183-1188.
8. DAME C, FAHNENSTICH H, FREITAG P et al.: Erythropoietin mRNA expression in human fetal and neonatal tissue. Blood (1998) 92:3218-3225.
9. FAHNENSTICH H, DAME C: Erythropoietin concentrations and erythropoiesis in newborns suffering from renal agenesis and congenital kidney diseases. Eur. J. Pediatr. (1996) 155:185-188.
10. LIN FK, SUGGS S, LIN CH et al.: Cloning and expression of the human erythropoietin gene. Proc. Natl Acad. Sci. USA (1985) 92:7850-7884.
11. JACOBS K, SHOEMAKER C, RUDERSDORF R et al.: Isolation and characterization of genomic cDNA clones of human erythropoietin. Nature (1985) 313:806-810.
12. ESBACH JW, EGRIE JC, DOWNING MT et al.: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: Results of a combined Phase I and II clinical trial. N. Engl. J. Med. (1987) 316:73-78.
13. GARBY L, SJOLIN S et al.: Studies on erythrokinetics in infancy: III. Plasma dissapearance and red cell uptake of intravenously injected radioiron. Acta Paediatr. (1963) 52:537-540.
14. DALLMAN PR, SIIMES MA: Percentile curves for hemoglobin and red cell volume in infancy and childhood. J. Pediatr. (1979) 94:28-33.
15. STOCKMANN JA III, GRAEBER JE, CLARK DA et al.: Anemia of prematurity: Determinants of erythropoietin response. J. Pediatr. (1984) 105:786-792.
16. BROWN MS, PHIBBS RH, GARCIA JF et al.: Postnatal changes in erythropoietin levels in untransfused premature infants. J. Pediatr. (1983) 103:612-617.
17. FORESTIER F, DAFFOS F, CATHERINE N, RENARD M, ANDREUX JP: Developmental hematopiesis in normal human fetal blood. Blood ( 1991) 11:2360-2363.
18. BROWN MS, GARCIA JF, PHIBBS RH et al.: Decreased response of plasma immunoreactive erythropoietin to 'available oxygen in anemia of prematurity. J. Pediatr. (1984) 105:793-798.
19. YAMASHITA H, KUKITA J, OHGA S et al.: Serum erythropoietin levels in term and preterm infants during the first year of life. Am J. Pediatr. Hematol. Oncol. (1994) 16:213-218.
20. TAN CC, ECKARDT KU, FIRTH JD et al.: Feedback modulation of renal and hepatic erythropoietin mRNA in response to graded anemia and hypoxia. Am. J. Physiol. (1992) 263: F474-481.
21. FREY B: Transfusion in premature infants impairs production and/or release of red blood cels, white blood cells and platelets. J. Paediatr. Child Health (2002) 38:265-267.
22. LIN JC, STRAUSS RG, KULHAVY JC et al.: Phlebotomy overdraw in the neonatal intensive care unit. Pediatrics (2000) 106:E19-E25.
23. BIFANO EM, CURRAN TR: Minimizing donor blood exposure in the neonatal intensive care unit. Clin. Perinatol. (1995) 22:657-669.
24. RHONDEAU SM, CHRISTENSEN RD, ROSS MP et al.: Responsiveness to recombinant human erythropoietin of marrow erythroid progenitors from infants with the 'anemia of prematurity'. J. Pediatr. (1988) 112:935-940.
25. HALPERIN DS, WACKER P, LACOURT G et al.: Effects of recombinant human erythropoietin in infants with the anemia of prematurity: A pilot study. J. Pediatr. (1990) 116:779-786.
26. SHANNON KM, MENTZER WC, ABELS RI et al.: Recombinant human erythropoietin in the anemia of prematurity: Results of a placebo-controlled pilot study. J. Pediatr. (1991) 118:949-955.
27. OHLS R, CHRISTENSEN RD: Recombinant erythropoietin compared with erythrocyte transfusion on the treatment of anemia of prematurity. J. Pediatr. (1991) 119:781-788.
28. BECK D, MASSEREY E, MEYER M et al.: Weekly intravenous administration of recombinant human erythropoietin in infants with the anemia of prematurity. Eur. J. Pediatr. (1991) 150:767-772.
29. HALPERIN DS, FELIX M, WACKER P et al.: Recombinant human erythropoietin in the treatment of infants with anemia of prematurity. Eur. J. Pediatr. (1992) 151:661-667.
30. GEORGE JW, BRACCO C, SHANNON K et al.: Response of Rhesus monkeys to recombinant human erythropoietin: Comparison of adults and infants. Pediatr. Res. (1989) 25:269A.
31. WIDNESS JA, VENG-PEDERSEN P, MODI NB et al.: Developmental differences in erythropoietin pharmacokinetics: Increased clearance and distribution in fetal and neonatal sheep. J. Pharmacol. Exp. Ther. (1992) 261:977-984.
32. RUTH V, WIDNESS J, CLEMONS G et al.: Postnatal changes in serum immunoreactive erythropoietin in relation to hypoxia before and after birth. J. Pediatr. (1990) 116:950-954.
33. BROWN MS, JONES MA, OHLS RK et al.: Single-dose pharmacokinetics of recombinant human erythropoietin in preterm infants after intravenous and subcutaneous administration. J. Pediatr. (1993) 122:655-658.
34. OHLS RK, VEERMAN MW, CHRISTENSEN RD: Pharmacokinetics of recombinant erythropoietin administered to preterm infants by continuous infusion in parenteral nutrition solution. J. Pediatr. (1996) 128:518-521.
35. DONATO H, RENDO P, VIVAS N, SCHVARTZMAN G, DIGREGORIO J, VAIN N: Recombinant human erythropoietin in the treatment of anemia of prematurity: A randomized, double-blind, placebo-controlled trial comparing three different doses. Int J. Pediatr. Hematol. Oncol. (1996) 3:279-285.
36. CARNIELLI V, MONTINI G, DARIOL R et al.: Effect of high doses of human recombinant erythropoietin on the need for blood transfusions in preterm infants. J. Pediatr. (1992) 121:98-102.
37. EMMERSON AJB, COLES HJ, STERN CMM et al.: Double blind trial of recombinant human erythropoietin in preterm infants. Arch. Dis. Child. (1993) 68:291-296.
38. MEYER MP, MEYER JH, COMMERFORD A et al.: Recombinant human erythropoietin in the treatment of the anemia of prematurity: Results of a double-blind, placebo-controlled study. Pediatrics (1994) 93:918-923.
39. SHANNON KM, KEITH JF, MENTZER WC et al.: Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. Pediatrics (1995) 95:1-8.
40. MAIER RF, OBLADEN M, SCIGALLA P et al.: The effect of Epoetin beta (recombinant human erythropoietin) on the need for transfusion in very-low-birth-weight infants. N. Engl. J. Med. (1994) 330:1173-1178.
41. OHLS RK, OSBORNE KA, CHRISTENSEN RD: Efficacy and cost analysis of treating very low birth weight infants with erythropoietin during their first two weeks of life: A randomized, placebo-controlled trial. J. Pediatr. (1995) 126:421-426,
42. OHLS RK, HARCUM J, SCHIBLER KR, CHRISTENSEN RD: The effect of erythropoietin on the transfusion requirements of preterm infans weighing 750 grams or less: a randomized, double-blind, placebo-controlled study. J. Pediatr. (1997) 131:661-665.
43. DONATO H, VAIN N, RENDO P et al.: Effect of early versus late administration of human recombinant erythropoietin on transfusion requirements in premature infants: Results of a randomized, placebo-controlled, multicenter trial. Pediatrics (2000) 105:1066-1072.
44. YEO CL, CHOO S, HO L: Effect of recombinant human erythropoietin on transfusion needs in preterm infants. J. Paediatr. Child Health (2001) 37:352-358.
45. OHLS RK, EHRENKRANZ RA, WRIGHT LL et al.: Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: A multicenter. randomized, controlled trial. Pediatrics (2001) 108:934-942.
46. MAIER RE, OBLADEN M, MULLER-HANSEN I et al.: Early treatment with erythropoietin β ameliorates anemia and reduces transfusion requirements in infants with birth weight below 1000 g. J. Pediatr. (2002) 141:8-15.
47. KOTTO-KOME AC, GARCÍA MG, CALHOUN DA, CHRISTENSEN RD: Effect of beginning recombinant erythropoietin treatment within the first week of life, among very-low-birth-weight neonates, on 'early' and 'late' erythrocyte transfusions: A meta-analysis. J. Perinatol. (2004) 24:24-29.
48. WIDNESS JA, SEWARD VJ, KROMER IJ, BURMEISTER LF, BELL EF, STRAUSS RG: Changing patterns of red blood cell transfusion in very low birth weight infants. J. Pediatr. (1996) 129:680-687.
49. MAIER RF, SONNTAG J, WALKA MM, LIU G, METZE BC, OBLADEN M: Changing practices of red blood cell transfusions in infants with birth weights less than 1000 g. J. Pediatr. (2000) 136:220-224.
50. IBOJIE J, GREISS M, LLOYD DJ, URBANIAK SJ: Donor exposure rate to transfusion ratio: a better discriminator of improvement in neonatal transfusion practice. Transf. Med. (2003) 13:287-291.
51. HILSENRATH P, NEMECHEK J, WIDNESS JA, CORDLE DG, STRAUSS RG: Cost-effectiveness of a limited donor blood program for neonatal red cell transfusions. Transfusion (1999) 39:938-943.
52. OHLS RK: Erythropoietin treatment in extremely low birth weight infants: Blood in versus blood out. J. Pediatr. (2002) 141:3-6.
53. OSKI FA, BARNESS LA: Vitamin E deficiency: A previously unrecognized cause of hemolytic anemia in the premature infant. J. Pediatr. (1967) 70:211-220.
54. ZIPURSKY: Vitamin E deficiency anemia in newborn infants. Clin. Perinatol. (1984) 11:393-402.
55. MILLARD DD, GIDDING SS, SOCOL ML et al.: Effects of intravascular, intrauterine transfusion on prenatal and postnatal hemolysis and erythropoiesis in severe fetal isoimmunization. J. Pediatr. (1990) 117:447-454.
56. KOENIG JM, ASHTON DR, DE VORE GR et al.: Late hyporegenerative anemia in Rh hemolytic disease. J. Pediatr. (1989) 115:315-318.
57. OHLS RK, WIRKUS PE, CHRISTENSEN RD: recombinant erythropoietin as treatment for the late hyporegenerative anemia of Rh hemolytic disease. Pediatrics (1992) 90:678-680.
58. SCARADAVOU A, INGLIS S, PETERSON P et al.: Suppression of erythropoiesis by intrauterine transfusions in hemolytic disease of the newborn: use of erythropoietin to treat the late anemia. J. Pediatr. (1993) 123:279-284.
59. NENADOV BECK M, DESSING C, VIAL Y, HOHLFELD P: Efficacy of recombinant human erythropoietin (rHuEpo) in anemic neonates after intrauterine transfusions. J. Pediatr. Hematol. Oncol. (1999) 21:333.
60. OVALI F, SAMANCI N, DAGOGLU T: Management of late anemia in rhesus hemolytic disease: use of recombinant human erythropoietin (a pilot study). Pediatr. Res. (1996) 39:831-834.
61. OVALY F: Late anaemia in Rh haemolytic disease. Arch. Dis. Child. Fetal Neonatal Ed. (2003) 88: F444-F446.
62. NICAISE C, GIRE C, CASHA P, D'ERCOLE C, CHAU C, PALIX C: Erythropoietin as treatment for late hyporegenerative anemia in neonates with Rh hemolytic disease after in utero exchange transfusion. Fetal Diagn. Ther. (2002) 17:22-24.
63. DHODAPKAR KM, BLEI F: Treatment of hemolytic disease of the newborn caused by anti-Kell antibody with recombinant erythropoietin. J. Pediatr. Hematol. Oncol. (2001) 23:69-70.
64. KREUZER KA, ROCKSTROH JK: Pathogenesis and pathophysiology of anemia in HIV infection. Ann. Hematol. (1997) 75:179-187:
65. RENDO P, FREIGEIRO D, BARBONI G, DONATO H, DRELICHMAN G, GONZALEZ A: A multicenter, randomized, double-blind trial with recombinant human erythropoietin (rHuEPO) in anemic HIV-infected children treated with antiretrovirals. Int. J. Pediatr. Hematol. Oncol. (2001) 7:235-239.
66. CASELLI D, MACCABRUNI A, ZUCOTI GV et al.: Recombinant erythropoietin for treatment of anaemia in HIV-infected children. AIDS (1996) 10:929-931.
67. LE CHENADEC J, MAYAUX MJ, GUIHENNEUC-JOUYAUX C, BLANCHE S: Enquete Perinatale Francaise Study Group: Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants. AIDS (2003) 17:2053-2061.
68. KLING PJ, SCHMIDT RL, ROBERTS RA, WIDNESS JA: Serum erythropoietin levels during infancy: associations with erythropoiesis. J. Pediatr. (1996) 128:791-795.
69. DELHOMMEAU F, CYNOBER T, SCHISCHMANOFF P, ROHRLICH P, DELAUNAY J, TCHERNIA G: Hereditary spherocytosis during the first year of life: natural history and transfusion need. Blood (2000) 95:393-399.
70. TCHERNIA G, DELHOMMEAU F, PERROTTA S et al.: Recombinant erythropoietin therapy as an alternative to blood transfusions in infants with hereditary spherocytosis. Hematol. J. (2001) 1:146-152.
71. KAYEMBA-KAYS'S S, CHRISTIN P, YAHOUANC-LAPALLE H, ORIOT D: Anémie néonatale par incompatibilité rhésus traitée par érythropoiétine. Arch. Pediatr. (2004) 11:868-869.
72. JUUL SE, JOYCE AE, ZHAO Y et al.: Why is erythropoietin present in human milk ? Studies of erythropoietin receptors on enterocytes of human and rat neonates. Pediatr. Res. (1999) 46:263-268.
73. JUUL SE: Recombinant erythropoietin as a neuroprotective treatment: in vitro and in vivo models. Clin. Perinatol. (2004) 31:129-142.
74. GHEZZI P, BRINES M: Erythropoietin as an antiapoptotic tissue-protective cytokine. Cell Death Differ. (2004) 11:S37-S44.
75. GENC S, KOROGLU TF, GENC K: Erythropoietin and the nervous system. Brain Res. (2004) 1000:19-31.
76. SAKANAKA M, WEN TC, MATSUDA S et al.: In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc. Natl Acad. Sci. USA (1998) 95:4635-4640.
77. SAKAMOTO Y, IGASE K, SAKANAKA M et al.: Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. Biochem. Biophys. Res. Comun. (1998) 253:26-32.
78. BERNAUDIN M, MARTI HH, ROUSSEL S et al.: A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J. Cereb. Blood Flow Metab. (1999) 19:643-651.
79. BUEMI M, ALLEGRA A, CORICA F et al.: Intravenous recombinant erythropoietin does not lead to an increase in cerebrospinal fluid erythropoietin concentration. Nephrol. Dial. Tranplant (2000) 15:422-423.
80. BRINES ML, GHEZZI P, KEENAN S et al.: Erythropoietin crosses the blood-brain barrier to protect against experimenal brain injury. Proc. Natl Acad. Sci. USA (2000) 97:10526-10531.
81. JUUL SE, MCPHERSON RJ, FARRELL FX, JOLLIFE L, NESS DJ, GLEASON CA: Erythropoietin concentrations in cerebrospinal fluid of nonhuman primates and fetal sheep following high-dose recombinant erythropoietin. Biol. Neonate (2004) 85:138-144.
82. EHRENREICH H, HASSELBLATT M, DEMBOWSKI C et al.: Erythropoietin therapy for acute stroke is both safe and beneficial. Mol. Med. (2002) 8:495-505.
83. KUMRAL A, BASKIN H, GOKMEN N et al.: Selective inhibition of nitric oxide in hypoxic-ischemic brain model in newborn rats: is it an explanation for the protective role of erythropoietin? Biol. Neonate (2004) 85:51-54:
84. KUMRAL A, OZER E, YILMAZ O et al.: Neuroprotective effect of erythropoietin on hypoxic-ischemic brain injury in neonatal rats. Biol. Neonate (2003) 83:224-228.
85. MAHESHWARI A: Role of cytokines in human intestinal villous development. Clin. Perinatol. (2004) 31:143-155.
86. CALHOUN DA, CHRISTENSEN RD: Hematopoietic growth factors in neonatal medicine: the use of enterally administered hematopoietic growth factors in the neonatal intensive care unit. Clin. Perinatol. (2004) 31:169-182.
87. JUUL SE, YACHNIS AT, CHRISTENSEN RD: Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum. Dev. (1998) 52:235-249.
88. LEDBETTER DJ, JUUL SE: Erythropoietin and necrotizing enterocolitis in the very low birth weight infant. Pediatr Surg (2000) 35:178-182.
89. BRITTON J, CHISTENSEN R: Enteral administration of recombinant erythropoietin to preterm infants. J. Perinatol. (1995) 15:281-283.
90. BALLIN A, BILKER-REICH A, ARBEL E, DAVIDOVITZ Y, KOHELET D: Erythropoietin, given enterally, stimulates erythropoiesis in premature infants. Lancet (1999) 353:1849.
91. SULLIVAN SE, CALHOUN DA, MAHESHWARI A et al.: Tolerance of simulated amniotic fluid in premature neonates. Ann. Pharmacother. (2002) 36:1518-1524.
92. LIMA-ROGEL V, CALHOUN DA, MAHESHWARI A et al.: Tolerance of a sterile isotonic electrolyte solution containing select recombinant growth factors in neonates recovering from necrotizing enterocolitis. J. Perinatol. (2003) 23:200-204.
93. RENDO P, BISCIGNIANO L, TURCONI A, SANCHEZ AVALOS JC, GRECO J: Tratamiento de la anemia en niños sometidos a hemodiálisis crónica con eritropoyetina humana recombinante. Medicina (1994) 54:392-398.
94. GAGNADOUX MF, LOIRAT C, BERTHELEME JP et al.: Treatment of anemia in hemodialyzed children using recombinant human erythropoietin (Eprex): results of a French multicenter clinical trial. Nephrologie (1994) 15:207-211.
95. NATIONAL KIDNEY FOUNDATION: K/DOQI Clinical practice guidelines for anemia of chronic kidney disease, 2000. Am. J. Kidney Dis. (2001) 37:S182-S238.
96. VAN DAMME-LOMBAERTS R, BROYER M, BUSINGER J et al.: A study of recombinant human erythropoietin in the treatment of anemia of chronic renal failure in children on haemodialysis. Pediatr. Nephrol. (1994) 8:338-342.
97. PORT RE, KIEPE D, VAN GUILDER M, JELLIFE RW, MEHLS O: Recombinant human erythropoietin for the treatment of renal anaemia in children. Clin. Pharmacokinet. (2004) 43:57-70.
98. RAO DS, SHIH MS, MOHINI R: Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N. Engl. J. Med. (1993) 328:171-174.
99. SUSUKI M: Analysis of the factors in the cases resistant to recombinant human erythropoietin treatment. Contrib. Nephrol. (1990) 82:65-71
100. CHAVERS BM, ROBERTS TL, HERZOG CA, COLLINS AJ, ST: PETER WL: Prevalence of anemia in erythropoietin-treated pediatric as compared to adult chronic dialysis patients. Kidney Int. (2004) 65:266-273.
101. FISHBANE S, MAESAKA JK: Iron management in end-stage renal disease. Am. J. Kidney Dis. (1997) 29:319-333.
102. SCHRODER CH: The European Pediatric Peritoneal Dialysis Working Group: The management of anemia in pediatric peritoneal dialysis patients. Guidelines by an ad hoc European committee. Pediatr. Nephrol. (2003) 18:805-809.
103. PIRAINO B, JOHNSTON JR: The use of subcutaneous erythropoietin in CAPD patients. Clin. Nephrol. (1990) 33:200-211.
104. YORGIN PD, BELSON A, SANCHEZ J et al.: Unexpectedly high prevalence of posttransplant anemia in pediatric and young adult renal transplant recipients. Am. J. Kidney Dis. (2002) 40:1306-1318.
105. AL-UZRI A, YORGIN PD, KLING PJ: Anemia in children after transplantation: etiology and the effect of immunosuppressive therapy on erythropoiesis. Pediatr. Transplant (2003) 7:253-264.
106. NIELSEN OJ, THAYSEN JH: Erythropoietin deficiency in acute renal failure. Lancet (1989) 1:624-625.
107. EXENI R, DONATO H, RENDO P et al.: Low levels of serum erythropoietin in children with endemic hemolytic uremic syndrome. Pediatr. Nephrol. (1998) 12:226-230.
108. O'BRIEN MER, CASEY S, TRELEAVEN J, POWLES TJ: Use of erythropoietin in the management of the haemolytic uraemic syndrome induced by mitomycin C/tamoxifen. Eur. J. Cancer (1994) 30:894-895.
109. CATALANO C, GIANESINI C, FABBIAN F: Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome. Nephron (2002) 91:324-326.
110. CITARRELLA P, GEBBIA V, TERESI M et al.: Hemolytic uremic syndrome after chemotherapy with gemcitabine and taxotere: a case report. Anti-Cancer Res. (2002) 22:1183-1185.
111. RIFKIN D, KRAVETZ HM, KNIGHT V, SCHADE AL: Urinary excretion of iron-binding protein in the nephrotic syndrome. N. Engl. J. Med. (1961) 265:115-118.
112. ELLIS D: Anemia in the course of the nephrotic syndrome secondary to transferrin depletion. J. Pediatr. (1977) 90:953-955.
113. VAZIRI ND, KAUPKE CJ, BARTON CH: GONZALES E: Plasma concentration and urinary excretion of erythropoietin in adult nephrotic syndrome. Am. J. Med. (1992) 92:35-40.
114. ZHOU KJ, VAZIRI ND: Erythropoietin metabolism and pharmacokinetics in experimental nephrosis. Am. J. Physiol. Renal Physiol (1992) 263: F812-F815.
115. FEINSTEIN S, BECKER-COHEN R, ALGUR N et al.: Erythropoietin deficiency causes anemia in nephrotic childen with normal kidney function. Am. J. Kidney Dis. (2001) 37:736-742.
116. GANSEVOORT RT, VAZIRI ND, DE JONG PE: Treatment of anemia of nephrotic syndrome with recombinant erythropoietin. Am. J. Kidney Dis. (1996) 28:274-277.
117. ISHIMITSU T, ONO H, SUGIYAMA M et al.: Sucessful erythropoietin treatment for severe anemia in nephrotic syndrome without renal dysfunction. Nephron (1996) 74:607-610.
118. BAYÉS B, SERRA A, JUNCÁ J, LAUZURICA R: Successful treatment of anaemia of nephrotic syndrome with recombinant human erythropoietin. Nephrol. Dial. Transplant. (1998) 13:1894-1895.
119. VAZIRI ND: Erythropoietin and transferrin metabolism in nephrotic syndrome. Am. J. Kidney Dis. (2001) 38:1-8.
120. KNIGHT K, WADE S, BALDUCCI L: Prevalence and outcomes of anemia in cancer: A systematic review of the literature. Am. J. Med. (2004) 116:11S-26S.
121. MICHON J: Incidence of anemia in pediatric cancer patients in Europe: Results of a large, international survey. Med. Pediatr. Oncol. (2002) 39:448-450.
122. MILLER CB, JONES RJ, PIANTADOSI S, ABELOFF MD, SPIVAK L: Decreased erythropoietin response in patients with the anemia of cancer. N. Engl. J. Med. (1990) 322:1689-1692.
123. FERRARIO E, FERRARI L, BIDOLI P et al.: Treatment of cancer-related anemia with epoetin alfa: a review. Cancer Treat. Rev. (2004) 30:563-575.
124. AAPRO M, SAN MIGUEL J: Evolving treatment strategies for anaemia in cancer: experience with epoetin beta. Ontology (2004) 67(Suppl. 1):17-22.
125. GLASPY J, BUKOWSKI R, STEINBERG D et al.: Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J. Clin. Oncol. (1997) 15:1218-1234.
126. DEMETRI GD, KRIS M, WADE J, DEGOS L, CELLA D, for the Procrit Study Group: Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. J. Clin. Oncol. (1998) 16:3412-3425.
127. RIZZO JD, LICHTIN AE, WOOLF SH et al.: Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J. Clin. Oncol. (2002) 20:4083-4107.
128. BOKEMEYER C, AAPRO MS, COURDI A et al.: EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur. J. Cancer (2004) 40:2201-2216.
129. GABRILOVE JL, CLEELAND CS, LIVINGSTON RB, SAROKHAN B, WINER E, EINHORN LH: Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J. Clin. Oncol. (2001) 19:2875-2882.
130. BOHLIUS J, LANGENSIEPEN S, SCHWRZER G et al.: Erythropoietin for patients with malignant disease (Cochrane Review): In: The Cochrane Library, Issue 3, John Wiley & Sons, Chichester (2004).
131. FEUSNER J, HASTINGS C: Recombinant human erythropoietin in pediatric oncology: a review. Med. Pediatr. Oncol. (2002) 39:463-468.
132. YILMAZ D, CETIMGUL N, KANTAR M, ONIZ H, KANSOY S, KAVAKLI K: A single institutional experience: is epoetin alpha effective in anemic children with cancer? Pediatr. Hematol. Oncol. (2004) 21:1-8:
133. ZOUBEK A, KRONBERGER M: Early epoetin alfa treatment in children with solid tumours. Med. Pediatr. Oncol. (2002) 39:459-462
134. BUYUKPAMUKCU M, VARAN A, KUTLUK T, AKYUZ C: Is epoetin alfa a treatment option for chemotherapy-related anemia in children? Med. Pediatr. Oncol. (2002) 39:455-458:
135. KRONBERGER M, FISCHMEISTER G, POERTSCHGER U, GADNER H, ZOUBEK A: Reduction in transfusion requirements with early epoetin alfa treatment in pediatric patients with solid tumors: a case-control study. Pediatr. Hematol. Oncol. (2002) 19:95-105.
136. WAGNER LM, BILLUPS CA, FURMAN WL, RAO NB, SANTANA VM: Combined use of erythropoioetin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: a randomized controlled trial. J. Clin. Oncol. (2004) 22:1886-1893.
137. SULLIVAN PS, HANSON DL, CHU SY et al.: Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: Results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood (1998) 91:301-308.
138. LEVINE AM: Anemia in the setting of cancer and human immunodeficiency virus. Clin. Infect. Dis. (2003) 37:S304-S314.
139. VOLBERDING P, for the Anemia in HIV Working Group: Consensus statement: anemia in HIV infection - current trends, treatment options, and practice strategies. Clin. Ther. (2000) 22:1004-1020.
140. BELPERIO PS, PHARM D, RHEW DC: Prevalence and outcomes of anemia in individuals with human immunodeficiency virus: A systematic review of the literature. Am. J. Med. (2004) 116:27S-43S.
141. BUSKIN SE, SULLIVAN PS: Anemia and its treatment and outcomes in persons infected with human immunodeficiency virus. Transfusion (2004) 44:826-832.
142. HENRY DH, BEALL GN, BENSON CA et al.: Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy: overview of four clinical trials. Ann. Intern. Med. (1992) 117:739-748.
143. BALFOUR HH: Recombinant human erythropoietin for treatment of anemia in persons with AIDS not receiving zidovudine. Int. J. Antimicrob. Agents (1997) 8:189-192.
144. GIMENEZ LF, SCHEEL PJ: Clinical application of recombinant erythropoietin in renal dialysis patients. Hematol. Oncol. Clin. N. Am. (1994) 8:913-926.
145. AFDHAL NH, DIETERICH DT, POCKROS PJ et al.: Epoetin alfa mantains ribavirin dose in HCV-infected patients: A prospective, double-blind, randomized controlled study. Gastroenterology (2004) 126:1302-1311.
146. ROSENZWEIG MQ, BENDER CM, LUCKE JP, YASKO JM, BRUFSKY AM: The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events. J. Pain Symptom Manage. (2004) 27:185-190.
147. BENNETT CL, LUMINARI S, NISSENSON AR et al.: Pure red-cell aplasia and epoetin therapy. N. Engl. J. Med. (2004) 351:1403-1408.